
ImmunityBio $IBRX Explodes Higher on EU Catalyst, Momentum Points to Further Upside
ImmunityBio (IBRX) surges over 30 percent after EU conditional authorization for Anktiva with BCG. Here’s why this regulatory breakthrough could mark the beginning of a larger revaluation.









